Dimerix LimitedASX: DXB

Dimerix at Canaccord Drug & Device and Ignite Conferences

Oct 11, 2026 at 5:32 PM EDT · Issued by Dimerix Limited via ASX

Filed with ASX · Oct 11, 2026 at 5:32 PM EDT · 35 pages · English

On 6ix: 6ix.com/news/dimerix-at-canaccord-drug-and-device-and-ignite-conferences

Release

For Immediate Release DIMERIX PRESENTATION FOR CANACCORD DRUG AND DEVICE 2026 CONFERENCE AND HONG KONG MEETINGS MELBOURNE, Australia, 12 October 2026: Dimerix Limited (ASX: DXB, “Dimerix”), a clinical-stage biopharmaceutical company developing treatments for kidney disease, is pleased to...

Dimerix Limited on 6ix

In the deck

Dimerix — Canaccord Genuity Drug and Device Conference 202635 slidesOct 12, 2026

Earlier from Dimerix

First Patient Reaches Four Years in DMX-200 Clinical ProgramOct 4
Notification regarding unquoted securities - DXBSep 28
Notification of 2026 Annual General Meeting DateSep 25
Dimerix Draws Down A$17M Under Non-Dilutive Funding FacilitySep 22
Dimerix Presents at ASX SMIDcaps Conference 2026Sep 22

Later from Dimerix

DMX-200 First 100 Patients Complete Phase 3 Trial TreatmentOct 15
Dimerix Announces Board Chair TransitionOct 18
2026 AGM Notice of Meeting, Letter of Access and Proxy FormOct 21
New Data Supports Biological Rationale for DMX-200 in FSGSOct 22
Dimerix Quarterly Activities Report and Appendix 4COct 28

All Dimerix news releases

Follow Dimerix into a list and get an email when it puts out news.

Follow Dimerix